Related Experiment Video

Updated: Sep 28, 2026

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

The relation between methods and recommendations in clinical practice guidelines for hypertension and hyperlipidemia

Atle Fretheim1, John W Williams, Andrew D Oxman

  • 1Department of Health Services Research, Norwegian Directorate for Health Social Welfare, PO Box 8054 Dep, N-0031 Oslo, Norway. atle.fretheim@shdir.no

The Journal of Family Practice
|December 18, 2002
PubMed

Insights

Clinical practice guidelines for hypertension and hyperlipidemia often lack rigorous development methods. This can lead to more aggressive treatment recommendations, impacting patient care.

Area of Science:

  • Cardiology
  • Clinical Practice Guidelines
  • Evidence-Based Medicine

Background:

  • Clinical practice guidelines (CPGs) aim to standardize patient care.
  • The methods used to develop CPGs may influence their recommendations.
  • Hypertension and hyperlipidemia management are areas with numerous CPGs.

Purpose of the Study:

  • To evaluate the relationship between the development methodologies of CPGs and their resultant recommendations.
  • To assess the rigor of methods used in CPGs for hypertension and hyperlipidemia.

Main Methods:

  • A systematic review of CPGs for hypertension or hyperlipidemia was conducted.
  • Two independent reviewers assessed guideline development using 8 predefined criteria.
  • Recommendations regarding treatment thresholds, initial drug selection, and screening aggressiveness were evaluated.

Main Results:

  • 33 CPGs were reviewed; only 6 met 5 or more of the 8 rigor criteria.
  • Fewer than 50% of guidelines met 5 specific criteria.
  • Significant variation in recommendations was observed.
  • Guidelines with less rigorous methods tended to suggest more aggressive interventions.
  • CPGs from specialty societies were less likely to meet rigor criteria.

Conclusions:

  • CPG developers employing less rigorous methods were more likely to advocate for aggressive interventions in hypertension and hyperlipidemia.
  • The quality of guideline development methods is associated with the aggressiveness of clinical recommendations.
Abstract

Related Concept Videos

Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Hypertension V: Nursing Management01:23

Hypertension V: Nursing Management

The nursing management of hypertension involves accurately assessing symptoms, making a comprehensive nursing diagnosis, collaborating with patients to set goals, and implementing targeted interventions to mitigate the condition's impact and improve patient well-being.Comprehensive AssessmentThe initial step in nursing care for hypertension involves a thorough patient assessment. It includes evaluating symptoms such as headaches, dizziness, blurred vision, and previous hypertension episodes.
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...